Shots:
- Alvotech and Teva reached a settlement and license agreement with Regeneron, allowing the US launch of AVT06, a biosimilar version of Eylea (aflibercept) in Q4’26 or earlier under certain conditions
- AVT06 is an aflibercept (Eylea) biosimilar that inhibits VEGF and has been approved as Mynzepli in the UK and EEA and as Aflibercept BS in Japan
- On Jan’24, Alvotech reported positive topline results showing AVT06 met its 1EP and demonstrated high similarity to Eylea in pts with wet AMD
Ref: Alvotech | Image: Alvotech and Teva |Press Release
Related News: Alvotech Reports the EC Approval of AVT03 (Biosimilar, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
